To find out how the latest drugs will Help Breast and Ovarian Cancer Patients in Eastern India with Gene Problems.
Not Applicable
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 2: C569- Malignant neoplasm of unspecifiedovary
- Registration Number
- CTRI/2023/11/059748
- Lead Sponsor
- INSTITUTE OF MEDICAL SCIENCES AND SUM HOSPITA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Newly diagnosed Breast and ovarian cancer patients greater than 18 years with HRD/BRCA gene alterations registered in the department of Medical Oncology, IMS and SUM hospital
Exclusion Criteria
1. Patients less than 18 years of age
2. Patients not meeting the above-mentioned criteria
3. Patients or patient relatives who do not consent to the testing
4. Patients with BRCA1 and/or BRCA2 mutations that are considered to be non-detrimental (eg, Variants of uncertain clinical significance ? or Variant of unknown significance ? or Variant, favor polymorphism ? or benign polymorphism, ? etc).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival (PFS)Timepoint: 2 years
- Secondary Outcome Measures
Name Time Method 1.To determine Overall survival among HRD/ BRCA positive Breast and ovary patients taking PARP inhibitors (Olaparib/Rucaparib). <br/ ><br>2.To determine Safety, Efficacy among HRD/ BRCA positive Breast and ovary patients taking PARP inhibitors (Olaparib/Rucaparib). <br/ ><br>3.To determine the prevalence of BRCA/ HRD positive mutations among breast and ovarian cancer patients <br/ ><br>4.Identifying the clinical and pathological profile of the patients testing positive for HRD/ g BRCA/t BRCA mutations. <br/ ><br>5.To find out the hindrances in doing HRD/ g BRCA/ t BRCA mutation testing and in obtaining PARP inhibitors (Olaparib/Rucaparib). <br/ ><br>Timepoint: 3years,5years